Navigation Links
Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. Additionally, preclinical data on INNO-206, a doxorubicin prodrug for the treatment of various cancers, will be presented. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to these presentations is as follows: -0-

Presentation Title:     "A phase I study of INNO-406, a dual inhibitor

                         of Abl/Lyn kinases, in adult patients with

                         imatinib-resistant or intolerant Philadelphia

                         chromosome positive (Ph+) leukemias"

----------------------- ----------------------------------------------

Abstract Number:        2637

----------------------- ----------------------------------------------

Session:                Poster Section 5, Clinical Research 11, Poster

                         Board #2

----------------------- ----------------------------------------------

Session Date and Time:  Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.

----------------------- ----------------------------------------------

Location:               Exhibit Hall, Los Angeles Convention Center

----------------------- ----------------------------------------------


----------------------- ----------------------------------------------

Presentation Title:     "Reduced chronic cardiotoxicity and

                         mitochondrial damage of the (6-

                         maleimidocaproyl) hydrazone derivative of

                         doxorubicin (DOXO-EMCH) in a rat model

                         compared to doxorubicin"

----------------------- ---------
'"/>




Page: 1 2 3

Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/10/2014)... Denver, CO (PRWEB) July 11, 2014 ... Vicki Cowart, President and CEO of Planned Parenthood of ... the fact Senator Mark Udall and Representative Diana DeGette ... the Supreme Court’s Hobby Lobby decision and keeping bosses ... and PPRM representatives listened to the president today in ...
(Date:7/10/2014)... 11, 2014 The Capital Institute for ... the first procedure in a clinical trial that delivers ... the leg. , During the procedure, done at Capital ... endovascular neurosurgeon, threaded a tiny catheter through the patient’s ... and neck and into the brain. Once the catheter ...
(Date:7/10/2014)... Mice consuming a supplement of omega 3 fatty acids ... saturated fats and omega 6 fatty acids, according to ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on ... not just obesity may contribute to worsening osteoarthritis. ... more significant role than mechanical factors in the link ...
(Date:7/10/2014)... 2014 More than 200 experts on ... urban street violence, will attend the 21st World Meeting ... (ISRA) at the Loews Atlanta Hotel, July 15-19. ... prestigious world meeting, which is held every other year ... bringing together leading scholars from more than 20 different ...
(Date:7/10/2014)... Fatigue, lack of safety equipment and ... accidents in the workplace, according to a series ... safety issues that contribute to the alarming workplace ... the job annually, according to the International Labor ... workplace accidents." , Safety Issue: "Extended Work Hours ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... 7 Vion,Pharmaceuticals, Inc. (Nasdaq Capital Market: VION) ... that the Company had regained,compliance with Marketplace Rule ... Stock had traded at $1.00 per share or ... Vion Pharmaceuticals, Inc. is committed to extending the ...
... MGT Capital Investments,Inc. (Amex: MGT ), ... ("HCIT") sector, today commented on the American Cancer,Society,s ... its colon cancer screening guidelines. MGT Capital Investment,s,Medicsight ... exchange under,"MDST," is an industry leader in the ...
... March 7 Novavax, Inc.,(Nasdaq: NVAX ) a ... and Chief Executive Officer, will be presenting at,the Partnering ... on March 11,2008 in Washington D.C. Dr. Singhvi will ... the area of vaccine development to,protect against H5N1 pandemic ...
... Calif., March 7 Genoptix, Inc.,(Nasdaq: GXDX ), ... in the 11th Annual Lehman Brothers Global,Health Care Conference ... Fla.,March 18 - 20, 2008., Dr. Tina Nova ... will present at the conference on Tuesday, March 18, ...
... to protect its Intellectual Property that, has been employed in Minimally Invasive ... ... decade, MARIETTA, Ga., March 7 In a much anticipated decision,Judge ... personally liable for expenses and attorneys,fees incurred by ERBE while defending against ...
... Liverpool School of Tropical Medicine has received a $30 million ... the control and treatment of malaria in pregnancy in Africa, ... directly benefit the 50 million women who face exposure to ... research at Liverpool and at 38 partner institutions in 27 ...
Cached Medicine News:Health News:Vion Pharmaceuticals Regains NASDAQ Listing Compliance 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 3Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 4Health News:Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference 2Health News:ERBE Perseveres Yet Again in Opposition to Dr. Jerome Canady, and is Awarded More Than One Million Dollars 2Health News:LSTM to lead $30 million research program into malaria in pregnancy 2
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
... The NMP22 BladderChek Test is the only ... diagnosis of bladder cancer. The NMP22 BladderChek Test ... a single urine sample, that detects elevated levels ... small amounts of NMP22 protein in the urine. ...
... The NMP22® Test Kit is a quantitative ... NMP22 protein. Healthy individuals generally have very small ... the level of NMP22 protein is often elevated ... even at early stages of the disease. The ...
... cystometry and urethral pressure profilometry. The ... bladder to be filled while cystometry ... the catheter in the bladder for ... is standing or sitting. Supplied sterile ...
Medicine Products: